BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma
- PMID: 21156281
- PMCID: PMC3030476
- DOI: 10.1016/j.ccr.2010.10.030
BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma
Abstract
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease composed of at least two distinct subtypes: germinal center B cell-like (GCB) and activated B cell-like (ABC) DLBCL. These phenotypic subtypes segregate with largely unique genetic lesions, suggesting the involvement of different pathogenetic mechanisms. In this report we show that the BLIMP1/PRDM1 gene is inactivated by multiple mechanisms, including homozygous deletions, truncating or missense mutations, and transcriptional repression by constitutively active BCL6, in ∼53% of ABC-DLBCL. In vivo, conditional deletion of Blimp1 in mouse B cells promotes the development of lymphoproliferative disorders recapitulating critical features of the human ABC-DLBCL. These results demonstrate that BLIMP1 is a bona fide tumor-suppressor gene whose loss contributes to lymphomagenesis by blocking plasma cell differentiation.
Copyright © 2010 Elsevier Inc. All rights reserved.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3030476/bin/nihms250122f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3030476/bin/nihms250122f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3030476/bin/nihms250122f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3030476/bin/nihms250122f4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3030476/bin/nihms250122f5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3030476/bin/nihms250122f6.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3030476/bin/nihms250122f7.gif)
Comment in
-
BLIMP1 against lymphoma: The verdict is reached.Cancer Cell. 2010 Dec 14;18(6):537-9. doi: 10.1016/j.ccr.2010.11.029. Cancer Cell. 2010. PMID: 21156275
Similar articles
-
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.J Exp Med. 2006 Feb 20;203(2):311-7. doi: 10.1084/jem.20052204. J Exp Med. 2006. PMID: 16492805 Free PMC article.
-
Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma.Cancer Cell. 2010 Dec 14;18(6):580-9. doi: 10.1016/j.ccr.2010.11.024. Cancer Cell. 2010. PMID: 21156282 Free PMC article.
-
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.Leukemia. 2017 Mar;31(3):625-636. doi: 10.1038/leu.2016.243. Epub 2016 Aug 29. Leukemia. 2017. PMID: 27568520 Free PMC article.
-
PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas.Leuk Lymphoma. 2015 May;56(5):1223-8. doi: 10.3109/10428194.2014.953155. Epub 2014 Oct 7. Leuk Lymphoma. 2015. PMID: 25115512 Review.
-
Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis.Hematology. 2002 Aug;7(4):239-52. doi: 10.1080/1024533021000024058. Hematology. 2002. PMID: 14972786 Review.
Cited by
-
TCP1 expression alters the ferroptosis sensitivity of diffuse large B-cell lymphoma subtypes by stabilising ACSL4 and influences patient prognosis.Cell Death Dis. 2024 Aug 22;15(8):611. doi: 10.1038/s41419-024-07001-0. Cell Death Dis. 2024. PMID: 39174525 Free PMC article.
-
Transcriptome and microbiome-immune changes across preinvasive and invasive anal cancer lesions.JCI Insight. 2024 Jul 18;9(16):e180907. doi: 10.1172/jci.insight.180907. JCI Insight. 2024. PMID: 39024554 Free PMC article.
-
Advances in biology, diagnosis and treatment of DLBCL.Ann Hematol. 2024 Sep;103(9):3315-3334. doi: 10.1007/s00277-024-05880-z. Epub 2024 Jul 17. Ann Hematol. 2024. PMID: 39017945 Review.
-
Understanding the intrinsic biology of diffuse large B-cell lymphoma: recent advances and future prospects.Int J Hematol. 2024 May 10. doi: 10.1007/s12185-024-03780-6. Online ahead of print. Int J Hematol. 2024. PMID: 38727950 Review.
-
Notch2 controls developmental fate choices between germinal center and marginal zone B cells upon immunization.Nat Commun. 2024 Mar 4;15(1):1960. doi: 10.1038/s41467-024-46024-1. Nat Commun. 2024. PMID: 38438375 Free PMC article.
References
-
- Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B cell lymphoma: moving toward a molecularly targeted approach. Blood. 2005;106:1164–1174. - PubMed
-
- Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511. - PubMed
-
- Angelin-Duclos C, Cattoretti G, Lin KI, Calame K. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J Immunol. 2000;165:5462–5471. - PubMed
-
- Basso K, Saito M, Sumazin P, Margolin AA, Wang K, Lim WK, Kitagawa Y, Schneider C, Alvarez MJ, Califano A, Dalla-Favera R. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood. 2010;115:975–984. - PMC - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases